nach oben

Journal of Neural Transmission

Erschienen in:

01.04.2009 | Basic Neurosciences, Genetics and Immunology - Original Article

Experience with long-term treatment with albumin-supplemented botulinum toxin type A

verfasst von: Bahram Mohammadi, Katja Kollewe, Maresa Wegener, Hans Bigalke, Reinhard Dengler

Erschienen in: Journal of Neural Transmission | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

In earlier studies, we have demonstrated the efficacy of albumin-supplemented botulinum toxin type A (ASBTA) in principle. Here, we present long-term data from 106 patients who received ASTBA over 5–10 years for the treatment of cervical dystonia, blepharospasm and hemifacial spasm. Vials of Dysport^® were diluted in 0.1% albumin solution to a concentration of 25 units/ml. Overall patients and indications, the mean latency to response was 7.1 ± 2.2 days, the mean duration of response was 12.3 ± 3.1 weeks and the mean global clinical improvement (scale 0–3) was 2.6 ± 0.2. Only one patient had neutralizing antibodies against BoNT-A. Side effects were less frequent than known for conventional BoNT-A and generally mild. These findings were confirmed by analysis of data of 71 patients who have been reconverted from ASBTA to conventional dilutions of Dysport^® or Botox^®. We conclude that long-term treatment with ASBTA is effective, safe and help to reduce costs.

Aoki K (1999) Preclinical update on Botox (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations. Eur J Neurol 6(Suppl 4):S3–S10CrossRef

Bhidayasiri R, Cardoso F, Truong DD (2006) Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations. Eur J Neurol 13(Suppl 1):21–29PubMedCrossRef

Bigalke H, Wohlfarth K, Irmer A, Dengler R (2001) Botulinum A toxin: Dysport improvement of biological availability. Exp Neurol 168(1):162–170PubMedCrossRef

Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005a) Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev (1):CD004900

Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005b) Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst Rev (1):CD004899

D’Costa DF, Abbott RJ (1991) Low dose botulinum toxin in spasmodic torticollis. J R Soc Med 84(11):650–651PubMed

Elston JS (1992) The management of blepharospasm and hemifacial spasm. J Neurol 239(1):5–8PubMedCrossRef

Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, Reiners C, Toyka KV (2000) Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 69(1):121–123PubMedCrossRef

Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin therapy: neutralizing and non-neutralizing antibodies—therapeutic consequences. Exp Neurol 147(1):96–102PubMedCrossRef

Greene P, Fahn S, Diamond B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9(2):213–217PubMedCrossRef

Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A (2004) Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 19(3):303–308PubMedCrossRef

Heckmann M, Plewig G (2005) Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study. Arch Dermatol 141(10):1255–1259PubMedCrossRef

Jankovic J (2004) Treatment of cervical dystonia with botulinum toxin. Mov Disord 19(Suppl 8):S109–S115PubMedCrossRef

Jankovic J, Schwartz K (1995) Response and immunoresistance to botulinum toxin injections. Neurology 45(9):1743–1746PubMed

Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60(7):1186–1188PubMed

Jitpimolmard S, Tiamkao S, Laopaiboon M (1998) Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry 64(6):751–757PubMedCrossRef

Jost WH (2006) Other indications of botulinum toxin therapy. Eur J Neurol 13(Suppl 1):65–69PubMedCrossRef

Kessler KR, Skutta M, Benecke R (1999) Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 246(4):265–274PubMedCrossRef

Laubis-Herrmann U, Fries K, Topka H (2002) Low-dose botulinum toxin-a treatment of cervical dystonia—a double-blind, randomized pilot study. Eur Neurol 47(4):214–221PubMedCrossRef

Marchetti A, Magar R, Findley L, Larsen JP, Pirtosek Z, Ruzicka E, Jech R, Slawek J, Ahmed F (2005) Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord 20(8):937–944PubMedCrossRef

Mejia NI, Vuong KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20(5):592–597PubMedCrossRef

Moore AP, Blumhardt LD (1991) A double blind trial of botulinum toxin “A” in torticollis, with one year follow-up. J Neurol Neurosurg Psychiatry 54(9):813–816PubMedCrossRef

Naumann M (2001) Evidence-based medicine: botulinum toxin in focal hyperhidrosis. J Neurol 248(Suppl 1):31–33PubMedCrossRef

Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, Kessler KR, Ceballos-Baumann AO, Ohly A, Oertel W, Kunig G (1998) What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 64(1):13–17PubMedCrossRef

Rollnik JD, Matzke M, Wohlfarth K, Dengler R, Bigalke H (2000) Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study. Eur Neurol 43(1):9–12PubMedCrossRef

Suputtitada A, Suwanwela NC (2005) The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil 27(4):176–184PubMedCrossRef

Suputtitada A, Phanthumchinda K, Locharernkul C, Suwanwela NC (2004) Hemifacial spasm: results of treatment with low dose botulinum toxin injection. J Med Assoc Thai 87(10):1205–1211PubMed

Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL (2005) Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 20(7):783–791PubMedCrossRef

Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre EC (1995) Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve 18(7):720–729PubMedCrossRef

Viriyavejakul A, Vachalathiti R, Poungvarin N (1998) Botulinum treatment for post-stroke spasticity: low dose regime. J Med Assoc Thai 81(6):413–422PubMed

Wohlfarth K, Goschel H, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 355(3):335–340PubMedCrossRef

Yu YL, Fong KY, Chang CM (1992) Treatment of idiopathic hemifacial spasm with botulinum toxin. Acta Neurol Scand 85(1):55–57PubMedCrossRef

Titel: Experience with long-term treatment with albumin-supplemented botulinum toxin type A
verfasst von: Bahram Mohammadi
Katja Kollewe
Maresa Wegener
Hans Bigalke
Reinhard Dengler
Publikationsdatum: 01.04.2009
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 4/2009
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-009-0200-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Auricular vagus somatosensory evoked potentials in vascular dementia

Accumbal noradrenaline that contributes to the alpha-adrenoceptor-mediated release of dopamine from reserpine-sensitive storage vesicles in the nucleus accumbens is derived from alpha-methyl-para-tyrosine-sensitive pools

Lamotrigine and valproic acid have different effects on motorcortical neuronal excitability

Lipopolysaccharide mitagates methamphetamine-induced striatal dopamine depletion via modulating local TNF-α and dopamine transporter expression

Na+,K+-ATPase activity in an animal model of mania

Neuregulin 1 and age of onset in the major psychoses